A Transformation-Defective Polyomavirus Middle T Antigen with a Novel Defect in PI3 Kinase Signaling

Deborah Denis1,2, Cecile Rouleau1,2, Brian S Schaffhausen3,2

  • 1Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA.

Journal of Virology
|November 18, 2016
PubMed

Insights

New murine polyomavirus middle T antigen (MT) mutants reveal novel phosphatidylinositol 3-kinase (PI3K) regulation. These mutants bind PI3K but fail to produce PIP3, blocking downstream signaling and transformation.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Middle T antigen (MT) from murine polyomavirus is a key oncogene driving tumor formation.
  • MT transforms cells by interacting with various cellular proteins, including PI3K, impacting cell regulation.
  • Previous MT mutants were defective due to impaired PI3K binding or membrane recruitment.

Purpose of the Study:

  • To investigate the transformation defect of novel MT mutants, specifically dl1015 and its derivatives (W348R, E349K).
  • To elucidate the mechanism by which these mutants fail to transform cells, focusing on PI3K signaling.
  • To uncover new regulatory mechanisms of PI3K signaling through the analysis of MT mutants.

Main Methods:

  • Analysis of MT mutants (dl1015, W348R, E349K) for transformation defects.
  • Assays for protein-protein interactions (e.g., with PP2A, YAP, Src, Shc, PI3K).
  • Measurement of kinase activity, protein phosphorylation, subcellular localization, and lipid product generation (PIP3).

Main Results:

  • The E349K MT mutant associates with PI3K similarly to wild-type MT but fails to activate downstream targets Akt and Rac-1.
  • Cells expressing the E349K mutant do not show elevated levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP3).
  • This indicates a defect in PI3K product generation, not enzyme binding or activation, explaining the transformation deficiency.

Conclusions:

  • The E349K MT mutant highlights a previously unrecognized regulatory step in PI3K signaling controlling PIP3 production.
  • This finding provides new insights into how MT oncogenic activity is regulated.
  • The study reveals novel aspects of mammalian cell regulation mediated by viral oncoproteins.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K